SCHEMBL5555600

SCHEMBL5555600

Cc1ccccc1C=C(C#N)C=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
TSHR P16473 3/20 0.48
MAPT P10636 5/20 0.42
KDM4E B2RXH2 4/20 0.42
TRPA1 O75762 1/20 0.37
LMNA P02545 5/20 0.36
KMT2A Q03164 3/20 0.36
PKM P14618 1/20 0.36
TP53 P04637 2/20 0.35
THRB P10828 2/20 0.35
CYP1A2 P05177 3/20 0.34
CYP2C19 P33261 2/20 0.34
NPC1 O15118 3/20 0.34
RAB9A P51151 3/20 0.34
CYP2C9 P11712 2/20 0.33
MEN1 O00255 2/20 0.33
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
BLM P54132 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5555599 1.00 ALDH1A1 (0.48) ALDH1A1TSHRMAPTKDM4ETRPA1
SCHEMBL27873486 0.82 MAPT (0.42) ALDH1A1TSHRMAPTKDM4ETRPA1
SCHEMBL14176101 0.79 NFE2L2 (0.42) ALDH1A1MAPTTRPA1LMNAKMT2A
SCHEMBL11550627 0.78 KDM4E (0.61) ALDH1A1MAPTKDM4ETRPA1LMNA
SCHEMBL11550629 0.78 KDM4E (0.61) ALDH1A1MAPTKDM4ETRPA1LMNA
SCHEMBL3369333 0.77 MAPT (0.63) ALDH1A1TSHRMAPTKDM4ETRPA1
SCHEMBL23892778 0.76 GABRA1 (0.50) ALDH1A1TSHRMAPTKDM4ETRPA1
SCHEMBL13800974 0.76 GABRA1 (0.50) ALDH1A1TSHRMAPTKDM4ETRPA1
SCHEMBL15933374 0.74 ALDH1A1 (0.44) ALDH1A1TSHRMAPTKDM4ETRPA1
SCHEMBL12173470 0.74 KDM4E (0.65) ALDH1A1KDM4ELMNAKMT2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1656351-B1 PROCESS FOR PREPARATION OF 4-ARYL-NICOTINAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2007-12-19 EP disclosed
US-7288658-B2 Process for preparation of pyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2007-10-30 US disclosed
EP-1656351-A1 PROCESS FOR PREPARATION OF 4-ARYL-NICOTINAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-05-17 EP disclosed
WO-2005014549-A1 PROCESS FOR PREPARATION OF 4-ARYL-NICOTINAMIDE DERIVATIVES F. HOFFMANN-LA-ROCHE AG (CH) 2005-02-17 WO disclosed
US-20050014792-A1 Process for preparation of pyridine derivatives ROCHE PALO ALTO LLC 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014792-A1 Process for preparation of pyridine derivatives NOX3, KMO, PBK ALDH1A1 1856/4885TSHR 2144/4885MAPT 4872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.